According to the new report entitled Treatment Algorithms in Rheumatoid Arthritis, this limited penetration is due primarily to payer restrictions on reimbursement; patients must often fail therapy on methotrexate before the high cost of biologics will be
According to the new report entitled Treatment Algorithms in Rheumatoid Arthritis, this limited penetration is due primarily to payer restrictions on reimbursement; patients must often fail therapy on methotrexate before the high cost of biologics will be
根据这一名为类风湿性关节炎的治疗方法的报告，生物制剂受到限制主要是因为支付人偿付受限；通常病人必须在接受氨甲蝶呤治疗失败后，费用很高的生物制剂才被医疗保险计划偿付。